武田制药股票讨论区

$武田制药(TAK.US)$ Takeda Says Primary And Key Secondary Endpoints Were Met In Narcolepsy Type 1 Phase 2b Trial;
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...

Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Caseys General Stores(CASY.US)$ - up 4.9%
2.$神经分泌生物科学(NBIX.US)$ - up 3.4%
3. $基立福(GRFS.US)$ - up 2.4%
4. $Stellantis NV(STLA.US)$ - up 1.1%
5. $武田制药(TAK.US)$ - up 1.1%
6. $诺华制药(NVS.US)$ - up 0.8%
7. $沃达丰(VOD.US)$ - up 0.7%
8. $齐昂银行(ZION.US)$ - up 0.6...

Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $韩国电力(KEP.US)$ - up 3.7%
2. $Unity Software(U.US)$ - up 2.9%
3. $网易(NTES.US)$ - up 1.7%
4. $桑坦德银行(SAN.US)$ - up 1.5%
5. $家乐氏(K.US)$ - up 1.5%
6. $Saia(SAIA.US)$ - up 0.9%
7. $英国保诚(PUK.US)$ - up 0.9%
8. $罗技(LOGI.US)$ - up 0...

$武田制药(TAK.US)$5年来营收除2021年下滑2.8%以外增涨了4年，2023年增长12.9%，5年平均增速17.8%，营业利润前4年连续高速增长，2023年下滑8%，5年平均增速21.3%，净利润受其他净收入影响较大，波动剧烈，2023年其他净收入较少，比较能体现核心盈利能力。
2023年利息费用占营业利润的22%，利息负担较重。
5年来资产负债率从62.4%下降到54.5%，应收账款在下降，存货有所上升，不过比例还算正常。
商誉达到4.79万亿，达到净资产6.35万亿的75%。
长期借款4.04万亿，达到净资产的64%，考虑到净资产中商誉占比，实际杠杆率很高。
5年来经营净额略高于投资净额，股东盈余不多。
目前市盈率27.4，和营业利润增速比有一定低估，但是负债表不是很好看，暂时观望。

$武田制药(TAK.US)$ shortage on adderal, wonder how much higher this price will go.